Storia in 2 fonti

Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. | After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.

Raccontata da

endpoints.news

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo7 h fa

Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio

originale

endpoints.news7 h fa

FDA warns Genzyme's Irish site over quality questions

FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.

Leggi questa versione → originale

Timeline cronologica

mercoledì 1 luglio 2026·endpoints.news
FDA warns Genzyme's Irish site over quality questions
FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.
mercoledì 1 luglio 2026·fiercepharma.com
Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. | After a…